Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
November 29, 2021, Mr. Hoonmo Lee tendered his resignation from the Board of Directors (the “Board”) of Indaptus Therapeutics,
Inc. (the “Company”), and from all committees of the Board. The resignation of Mr. Lee was effective immediately and was
not the result of any disagreement with the Company, its management, the Board, or any committee of the Board on any matter relating
to the Company’s operations, policies or practices.
On
the same day, the Board elected Mark J. Gilbert, M.D. as a member of the Board, effective immediately. Dr. Gilbert will serve as a Class
I director, succeeding Mr. Lee, with a term expiring at the Company’s annual meeting of stockholders to be held in 2022, and until
his successor is elected and qualified or until his earlier death, resignation or removal.
Dr.
Gilbert, 61, brings more than 30 years of experience in global medical and clinical research and development, and management of medical
affairs. Since March 2019, Dr. Gilbert serves as Executive Vice President of Research and Development at Acepodia, Inc., a clinical-stage
biotechnology company addressing gaps in cancer care and since June 2021, Dr. Gilbert has served as a Clinical Development Advisor to
Decoy Biosystems, Inc., the Company’s wholly owned-subsidiary. In addition, from October 2020, Dr. Gilbert serves as the Chairman
of the Scientific Advisory Board at Inceptor Bio, LLC, a biotechnology company developing multiple next-generation cell and gene therapy
platforms for underserved and difficult-to-treat cancers and from October 2020, he serves as a Strategic Advisor at Kineticos Ventures,
a firm providing advisory services and capital to emerging life sciences firms. Prior to these positions, between November 2013 and January
2020, Dr. Gilbert was the Chief Medical Officer of Juno Therapeutics Inc., a biopharmaceutical company, where he led the clinical development
of some of the first CAR-T cell therapies. Before that, Dr. Gilbert held leadership positions at Bayer Schering Pharma AG, where he served
as Vice President and Head of Global Clinical Development, Therapeutic Area Oncology; Berlex Pharmaceuticals, Inc., where he served as
Vice President of Medical Affairs, Oncology, and Vice President and Head of Global Medical Development Group, Oncology; and Immunex Corporation,
where he served as Senior Medical Director, Clinical Research and Development. Between May 2019 and May 2021, Dr. Gilbert served as an
Independent Director of Silicon Therapeutics, Inc., a fully integrated drug design and development company. Dr. Gilbert earned a Bachelor
of Science degree in Biochemistry from the University of Iowa and a Medical Doctor degree from the University of Iowa College of Medicine.
He trained in internal medicine, infectious disease and medical oncology at the University of California, San Francisco, and the University
of Washington, respectively.
In
connection with Dr. Gilbert’s appointment to the Board, on December 1, 2021, Dr. Gilbert was granted a stock option to purchase
20,000 shares of common stock at an exercise price of $5.35 per share. The stock options shall vest in full on the first anniversary
of the grant date, subject to continued service on the Board and the options shall also vest in full immediately upon a change of control.
In addition, and consistent with the Company’s non-employee directors compensation policy, Dr. Gilbert will be eligible to receive
an annual retainer of $50,000 and will also be reimbursed for reasonable out-of-pocket business expenses incurred in connection with
attending meetings of the Board and in connection with other business related to the Board. Furthermore, Dr. Gilbert will be entitled
to a grant of stock options for such number of shares of common stock of the Company equal to a Black-Scholes value of $75,000 on the
grant date, as determined by the Company’s Compensation Committee, on the date of each board meeting coincident with or immediately
following the Company’s annual meeting, beginning with the annual meeting of stockholders for 2022. Such stock options shall vest
in full on the first anniversary of the grant date, subject to continued service on the Board and the options shall also vest in full
immediately upon a change of control.
There
are no family relationships between Dr. Gilbert and any director or executive officer of the Company. There were no other arrangements
or understandings between Dr. Gilbert and any other person pursuant to which Dr. Gilbert was selected as a director, and there are and
have been no transactions since the beginning of the Company’s last fiscal year, or currently proposed, regarding Dr. Gilbert that
are required to be disclosed by Item 404(a) of Regulation S-K.
Dr.
Gilbert also executed the Company’s standard form of indemnification agreement, a copy of which has been filed as Exhibit 10.5
to the Company’s Form 8-K filed with the Securities and Exchange Commission on August 6, 2021.